ATE253939T1 - Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid- immunomodulator - Google Patents
Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid- immunomodulatorInfo
- Publication number
- ATE253939T1 ATE253939T1 AT01927674T AT01927674T ATE253939T1 AT E253939 T1 ATE253939 T1 AT E253939T1 AT 01927674 T AT01927674 T AT 01927674T AT 01927674 T AT01927674 T AT 01927674T AT E253939 T1 ATE253939 T1 AT E253939T1
- Authority
- AT
- Austria
- Prior art keywords
- fungal
- inhibitor
- squalenepoxidase
- pharmaceutical composition
- composition containing
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 230000002584 immunomodulator Effects 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 239000003120 macrolide antibiotic agent Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002538 fungal effect Effects 0.000 abstract 4
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract 1
- 229940123185 Squalene epoxidase inhibitor Drugs 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 abstract 1
- 229960002722 terbinafine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003932.1A GB0003932D0 (en) | 2000-02-18 | 2000-02-18 | Pharmaceutical compositions |
| PCT/EP2001/001744 WO2001060345A2 (en) | 2000-02-18 | 2001-02-16 | Pharmaceutical composition comprising squalene epoxidase inhibitor and macrolide immunomodulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE253939T1 true ATE253939T1 (de) | 2003-11-15 |
Family
ID=9886001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01927674T ATE253939T1 (de) | 2000-02-18 | 2001-02-16 | Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid- immunomodulator |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6919317B2 (de) |
| EP (1) | EP1255564B1 (de) |
| JP (1) | JP3841682B2 (de) |
| CN (1) | CN100400103C (de) |
| AT (1) | ATE253939T1 (de) |
| AU (1) | AU2001254647A1 (de) |
| BR (1) | BR0108403A (de) |
| CA (1) | CA2399971C (de) |
| DE (1) | DE60101213T2 (de) |
| DK (1) | DK1255564T3 (de) |
| ES (1) | ES2210150T3 (de) |
| GB (1) | GB0003932D0 (de) |
| HK (1) | HK1052633A1 (de) |
| PT (1) | PT1255564E (de) |
| TR (1) | TR200400227T4 (de) |
| WO (1) | WO2001060345A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001928D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| GB0125443D0 (en) | 2001-10-23 | 2001-12-12 | Novartis Ag | Organic Compounds |
| US7452692B2 (en) * | 2002-02-13 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Method for extracting a macrolide from biomatter |
| AU2003272471B2 (en) | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| WO2004071510A1 (en) * | 2003-02-11 | 2004-08-26 | Cipla Ltd | Pharmaceutical composition comprising immunosuppressants for the treatment of dermatophytosis |
| GB0307869D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| GB0307866D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| GB0307867D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| GB0307864D0 (en) * | 2003-04-04 | 2003-05-14 | Novartis Ag | Pharmaceutical composition |
| ES2389443T3 (es) * | 2004-04-08 | 2012-10-26 | Meda Pharma S.À.R.L. | Composición de espuma de pimecrolimus que contiene hexilenglicol, opcionalmente alcohol de oleílo, dimetilisosorbida y/o triglicéridos de cadena media |
| US8637070B2 (en) | 2005-02-09 | 2014-01-28 | Santen Pharmaceutical Co., Ltd. | Rapamycin formulations and methods of their use |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| WO2006103638A2 (en) * | 2005-03-31 | 2006-10-05 | Ranbaxy Laboratories Limited | Topical pharmaceutical compositions of terbinafine and processes for their preparation |
| GB0508827D0 (en) * | 2005-04-29 | 2005-06-08 | Novartis Ag | Cosmeceutical composition |
| US20090082469A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched terbinafine |
| WO2011035225A1 (en) * | 2009-09-21 | 2011-03-24 | President And Fellows Of Harvard College | Synergistic combination therapy |
| EP3741367A1 (de) | 2019-05-21 | 2020-11-25 | Premark Pharma GmbH | Behandlung von augenerkrankungen |
| WO2024209038A1 (en) | 2023-04-06 | 2024-10-10 | Premark Pharma Gmbh | Use of pimecrolimus for the treatment of dry eye in patients characterized by a corneal staining score of 4 or 5 on the oxford grading scale |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3244592A (en) * | 1962-06-09 | 1966-04-05 | Arai Tadashi | Ascomycin and process for its production |
| NZ235991A (en) | 1989-11-09 | 1993-05-26 | Sandoz Ltd | Macrolide compounds and pharmaceutical compositions thereof |
| HU223343B1 (hu) * | 1991-05-20 | 2004-06-28 | Novartis Ag. | Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására |
| KR100434682B1 (ko) * | 1994-10-26 | 2004-08-18 | 노바티스 아게 | 약학조성물 |
| GB9509631D0 (en) * | 1995-05-12 | 1995-07-05 | Sandoz Ltd | Antifungal combination |
| DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
| WO1999017760A2 (en) * | 1997-10-02 | 1999-04-15 | Microcide Pharmaceuticals, Inc. | Fungal or mammalian cell efflux pump inhibitors for enhancing susceptibility of the cell to a drug |
-
2000
- 2000-02-18 GB GBGB0003932.1A patent/GB0003932D0/en not_active Ceased
-
2001
- 2001-02-16 ES ES01927674T patent/ES2210150T3/es not_active Expired - Lifetime
- 2001-02-16 BR BR0108403-8A patent/BR0108403A/pt not_active Application Discontinuation
- 2001-02-16 PT PT01927674T patent/PT1255564E/pt unknown
- 2001-02-16 AU AU2001254647A patent/AU2001254647A1/en not_active Abandoned
- 2001-02-16 CN CNB018050913A patent/CN100400103C/zh not_active Expired - Fee Related
- 2001-02-16 AT AT01927674T patent/ATE253939T1/de not_active IP Right Cessation
- 2001-02-16 US US10/204,027 patent/US6919317B2/en not_active Expired - Fee Related
- 2001-02-16 TR TR2004/00227T patent/TR200400227T4/xx unknown
- 2001-02-16 DE DE60101213T patent/DE60101213T2/de not_active Expired - Fee Related
- 2001-02-16 DK DK01927674T patent/DK1255564T3/da active
- 2001-02-16 WO PCT/EP2001/001744 patent/WO2001060345A2/en active IP Right Grant
- 2001-02-16 EP EP01927674A patent/EP1255564B1/de not_active Expired - Lifetime
- 2001-02-16 CA CA002399971A patent/CA2399971C/en not_active Expired - Fee Related
- 2001-02-16 JP JP2001559443A patent/JP3841682B2/ja not_active Expired - Fee Related
-
2003
- 2003-05-13 HK HK03103361A patent/HK1052633A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2399971A1 (en) | 2001-08-23 |
| BR0108403A (pt) | 2003-03-11 |
| ES2210150T3 (es) | 2004-07-01 |
| JP2003522783A (ja) | 2003-07-29 |
| EP1255564B1 (de) | 2003-11-12 |
| DK1255564T3 (da) | 2004-02-09 |
| CN1400909A (zh) | 2003-03-05 |
| HK1052633A1 (en) | 2003-09-26 |
| GB0003932D0 (en) | 2000-04-12 |
| DE60101213T2 (de) | 2004-08-19 |
| WO2001060345A2 (en) | 2001-08-23 |
| PT1255564E (pt) | 2004-03-31 |
| EP1255564A2 (de) | 2002-11-13 |
| CN100400103C (zh) | 2008-07-09 |
| US20030100517A1 (en) | 2003-05-29 |
| DE60101213D1 (de) | 2003-12-18 |
| JP3841682B2 (ja) | 2006-11-01 |
| TR200400227T4 (tr) | 2004-04-21 |
| WO2001060345A3 (en) | 2002-04-18 |
| CA2399971C (en) | 2009-10-06 |
| US6919317B2 (en) | 2005-07-19 |
| AU2001254647A1 (en) | 2001-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE253939T1 (de) | Pharmazeutische zusammensetzung enthaltend einen squalenepoxidasehemmer und einen makrolid- immunomodulator | |
| WO2006013441A3 (en) | Use of probiotic bacteria for the preparation of topical compositions for skin protection | |
| TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
| SG162773A1 (en) | Flavonoid compounds and uses thereof | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| ECSP034447A (es) | Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis | |
| WO2006136420A3 (en) | Methods and means for protecting the skin against pathogenic microorganisms | |
| WO2007014372A3 (en) | Compositions and methods for treating bacteria | |
| CL2012001080A1 (es) | Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida. | |
| UY27720A1 (es) | Aroilpiridinonas monocíclicas, | |
| TW200605870A (en) | Topical methadone compositions and methods for using the same | |
| MX2010003916A (es) | Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih). | |
| WO2003065988A3 (en) | A combination for treating cold and cough | |
| NO20052362L (no) | Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner | |
| WO2006116221A3 (en) | Therapeutic combinations for the treatment or prevention of psychotic disorders | |
| MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
| RS20050739A (en) | Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases | |
| TW200621799A (en) | Acylated nonadepsipeptides II | |
| PA8571501A1 (es) | Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa | |
| GR20020100478A (el) | Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης | |
| UY30629A1 (es) | Nuevo péptido de actinomadura namibiensis | |
| NO20051261L (no) | Morfin-6-glukuronidsalt | |
| WO2005107871A3 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury | |
| EP2250887A3 (de) | Verwendung des nicht antibakterielle Tetrazyklin-analog CMT-1002, und Zubereitungen daraus, zur Behandlung von bakteriellen Exotoxinen | |
| IL174134A0 (en) | Use of a protein in the preparation of a medicament for treatment of fibrotic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1255564 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |